Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
fosaprepitant (fosaprepitant dimeglumine)
Merck Sharp & Dohme B.V.
A04AD12
fosaprepitant (fosaprepitant dimeglumine)
150mg
powder lyophilized for solution for infusion
(1) glass vial 10ml
Prescription
Registered
2021-03-17
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT EMEND 150 mg powder for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains fosaprepitant dimeglumine equivalent to 150 mg fosaprepitant, which corresponds to 130.5 mg of aprepitant. After reconstitution and dilution 1 ml of solution contains 1 mg fosaprepitant (1 mg/ml) (see section 6.6). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for infusion. White to off-white amorphous powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. EMEND 150 mg is given as part of a combination therapy (see section 4.2). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults_ The recommended dose is 150 mg administered as an infusion OVER 20-30 MINUTES on Day 1, initiated approximately 30 minutes prior to chemotherapy (see section 6.6). EMEND should be administered in conjunction with a corticosteroid and a 5-HT3 antagonist as specified in the tables below. 3 The following regimens are recommended for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy. _Highly Emetogenic Chemotherapy Regimen_ Day 1 Day 2 Day 3 Day 4 EMEND 150 mg intravenously none none none Dexamethasone 12 mg orally 8 mg orally 8 MG ORALLY TWICE DAILY 8 MG ORALLY TWICE DAILY 5-HT 3 antagonists Standard dose of 5-HT 3 antagonists. See the product information for the selected 5-HT 3 antagonist for appropriate dosing information none none none DEXAMETHASONE should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 to 4. Dexamethasone should also be administered in the evenings on Days 3 and 4. The dose of dexamethasone accounts for active substance interactions. _Moderately Emetogenic Chemotherapy Regimen_ Day 1 EMEND 150 mg intravenously Dexamethasone 12 mg ora Read the complete document